Global Antibacterial (Drug) Resistance Market Outlook 2021

Table of Contents

1 Antibacterial (Drug) Resistance Market Overview
1.1 Product Overview and Scope of Antibacterial (Drug) Resistance
1.2 Antibacterial (Drug) Resistance Segment by Type
1.2.1 Global Antibacterial (Drug) Resistance Sales Growth Rate Comparison by Type (2020-2026)
1.2.2 Telavancin (Vibativ)
1.2.3 Ceftaroline Fosamil (Teflaro/ Zinforo)
1.2.4 Fidaxomicin (Dificid / Dificlir)
1.2.5 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
1.2.6 Dalbavancin (Dalvance/ Xydalba)
1.2.7 Tedizolid Phosphate (Sivextro)
1.2.8 Oritavancin (Orbactiv/ Nuvocid)
1.2.9 Ceftolozane-Tazobactam (Zerbaxa)
1.2.10 Ceftazidime-Avibactam (Avycaz/ Zavicefta)
1.2.11 PHASE III DRUGS
1.3 Antibacterial (Drug) Resistance Segment by Indication
1.3.1 Antibacterial (Drug) Resistance Sales Comparison by Indication: (2020-2026)
1.3.2 Complicated Urinary Tract Infection (CUTI)
1.3.3 Complicated Intra-Abdominal Infections (CIAI)
1.3.4 Blood Stream Infections (BSI)
1.3.5 Clostridium Difficile Infections (CDI)
1.3.6 Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
1.3.7 Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
1.3.8 Community Acquired Bacterial Pneumonia (CABP)
1.4 Global Antibacterial (Drug) Resistance Market Size Estimates and Forecasts
1.4.1 Global Antibacterial (Drug) Resistance Revenue 2015-2026
1.4.2 Global Antibacterial (Drug) Resistance Sales 2015-2026
1.4.3 Antibacterial (Drug) Resistance Market Size by Region: 2020 Versus 2026

2 Global Antibacterial (Drug) Resistance Market Competition by Manufacturers
2.1 Global Antibacterial (Drug) Resistance Sales Market Share by Manufacturers (2015-2020)
2.2 Global Antibacterial (Drug) Resistance Revenue Share by Manufacturers (2015-2020)
2.3 Global Antibacterial (Drug) Resistance Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Antibacterial (Drug) Resistance Manufacturing Sites, Area Served, Product Type
2.5 Antibacterial (Drug) Resistance Market Competitive Situation and Trends
2.5.1 Antibacterial (Drug) Resistance Market Concentration Rate
2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key Antibacterial (Drug) Resistance Players (Opinion Leaders)

3 Antibacterial (Drug) Resistance Retrospective Market Scenario by Region
3.1 Global Antibacterial (Drug) Resistance Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Antibacterial (Drug) Resistance Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Antibacterial (Drug) Resistance Market Facts & Figures by Country
3.3.1 North America Antibacterial (Drug) Resistance Sales by Country
3.3.2 North America Antibacterial (Drug) Resistance Sales by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Antibacterial (Drug) Resistance Market Facts & Figures by Country
3.4.1 Europe Antibacterial (Drug) Resistance Sales by Country
3.4.2 Europe Antibacterial (Drug) Resistance Sales by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Antibacterial (Drug) Resistance Market Facts & Figures by Region
3.5.1 Asia Pacific Antibacterial (Drug) Resistance Sales by Region
3.5.2 Asia Pacific Antibacterial (Drug) Resistance Sales by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Antibacterial (Drug) Resistance Market Facts & Figures by Country
3.6.1 Latin America Antibacterial (Drug) Resistance Sales by Country
3.6.2 Latin America Antibacterial (Drug) Resistance Sales by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Antibacterial (Drug) Resistance Market Facts & Figures by Country
3.7.1 Middle East and Africa Antibacterial (Drug) Resistance Sales by Country
3.7.2 Middle East and Africa Antibacterial (Drug) Resistance Sales by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Antibacterial (Drug) Resistance Historic Market Analysis by Type
4.1 Global Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
4.2 Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2015-2020)
4.3 Global Antibacterial (Drug) Resistance Price Market Share by Type (2015-2020)
4.4 Global Antibacterial (Drug) Resistance Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Global Antibacterial (Drug) Resistance Historic Market Analysis by Indication
5.1 Global Antibacterial (Drug) Resistance Sales Market Share by Indication (2015-2020)
5.2 Global Antibacterial (Drug) Resistance Revenue Market Share by Indication (2015-2020)
5.3 Global Antibacterial (Drug) Resistance Price by Indication (2015-2020)

6 Company Profiles and Key Figures in Antibacterial (Drug) Resistance Business
6.1 Melinta Therapeutics
6.1.1 Corporation Information
6.1.2 Melinta Therapeutics Description, Business Overview
6.1.3 Melinta Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Melinta Therapeutics Products Offered
6.1.5 Melinta Therapeutics Recent Development
6.2 Allergan
6.2.1 Allergan Corporation Information
6.2.2 Allergan Description, Business Overview
6.2.3 Allergan Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.2.4 Allergan Products Offered
6.2.5 Allergan Recent Development
6.3 Merck
6.3.1 Merck Corporation Information
6.3.2 Merck Description, Business Overview
6.3.3 Merck Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.3.4 Merck Products Offered
6.3.5 Merck Recent Development
6.4 Abbott Laboratories
6.4.1 Abbott Laboratories Corporation Information
6.4.2 Abbott Laboratories Description, Business Overview
6.4.3 Abbott Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Abbott Laboratories Products Offered
6.4.5 Abbott Laboratories Recent Development
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description, Business Overview
6.5.3 Pfizer Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.5.4 Pfizer Products Offered
6.5.5 Pfizer Recent Development
6.6 GSK
6.6.1 GSK Corporation Information
6.6.2 GSK Description, Business Overview
6.6.3 GSK Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.6.4 GSK Products Offered
6.6.5 GSK Recent Development
6.7 PENDOPHARM
6.6.1 PENDOPHARM Corporation Information
6.6.2 PENDOPHARM Description, Business Overview
6.6.3 PENDOPHARM Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.4.4 PENDOPHARM Products Offered
6.7.5 PENDOPHARM Recent Development
6.8 Absynth Biologics
6.8.1 Absynth Biologics Corporation Information
6.8.2 Absynth Biologics Description, Business Overview
6.8.3 Absynth Biologics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.8.4 Absynth Biologics Products Offered
6.8.5 Absynth Biologics Recent Development
6.9 Achaogen
6.9.1 Achaogen Corporation Information
6.9.2 Achaogen Description, Business Overview
6.9.3 Achaogen Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.9.4 Achaogen Products Offered
6.9.5 Achaogen Recent Development
6.10 Acino Holdings
6.10.1 Acino Holdings Corporation Information
6.10.2 Acino Holdings Description, Business Overview
6.10.3 Acino Holdings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.10.4 Acino Holdings Products Offered
6.10.5 Acino Holdings Recent Development
6.11 Aventis Pharma
6.11.1 Aventis Pharma Corporation Information
6.11.2 Aventis Pharma Antibacterial (Drug) Resistance Description, Business Overview
6.11.3 Aventis Pharma Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.11.4 Aventis Pharma Products Offered
6.11.5 Aventis Pharma Recent Development
6.12 Austell Laboratories
6.12.1 Austell Laboratories Corporation Information
6.12.2 Austell Laboratories Antibacterial (Drug) Resistance Description, Business Overview
6.12.3 Austell Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.12.4 Austell Laboratories Products Offered
6.12.5 Austell Laboratories Recent Development
6.13 Assembly Biosciences
6.13.1 Assembly Biosciences Corporation Information
6.13.2 Assembly Biosciences Antibacterial (Drug) Resistance Description, Business Overview
6.13.3 Assembly Biosciences Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.13.4 Assembly Biosciences Products Offered
6.13.5 Assembly Biosciences Recent Development
6.14 Arpida
6.14.1 Arpida Corporation Information
6.14.2 Arpida Antibacterial (Drug) Resistance Description, Business Overview
6.14.3 Arpida Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.14.4 Arpida Products Offered
6.14.5 Arpida Recent Development
6.15 Demuris
6.15.1 Demuris Corporation Information
6.15.2 Demuris Antibacterial (Drug) Resistance Description, Business Overview
6.15.3 Demuris Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.15.4 Demuris Products Offered
6.15.5 Demuris Recent Development
6.16 Evolva Holding
6.16.1 Evolva Holding Corporation Information
6.16.2 Evolva Holding Antibacterial (Drug) Resistance Description, Business Overview
6.16.3 Evolva Holding Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.16.4 Evolva Holding Products Offered
6.16.5 Evolva Holding Recent Development
6.17 ContraFect
6.17.1 ContraFect Corporation Information
6.17.2 ContraFect Antibacterial (Drug) Resistance Description, Business Overview
6.17.3 ContraFect Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.17.4 ContraFect Products Offered
6.17.5 ContraFect Recent Development
6.18 Cerexa
6.18.1 Cerexa Corporation Information
6.18.2 Cerexa Antibacterial (Drug) Resistance Description, Business Overview
6.18.3 Cerexa Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.18.4 Cerexa Products Offered
6.18.5 Cerexa Recent Development
6.19 InterMune
6.19.1 InterMune Corporation Information
6.19.2 InterMune Antibacterial (Drug) Resistance Description, Business Overview
6.19.3 InterMune Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.19.4 InterMune Products Offered
6.19.5 InterMune Recent Development
6.20 Isis Pharmaceuticals
6.20.1 Isis Pharmaceuticals Corporation Information
6.20.2 Isis Pharmaceuticals Antibacterial (Drug) Resistance Description, Business Overview
6.20.3 Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.20.4 Isis Pharmaceuticals Products Offered
6.20.5 Isis Pharmaceuticals Recent Development
6.21 Lyndra
6.21.1 Lyndra Corporation Information
6.21.2 Lyndra Antibacterial (Drug) Resistance Description, Business Overview
6.21.3 Lyndra Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.21.4 Lyndra Products Offered
6.21.5 Lyndra Recent Development
6.22 Microbecide
6.22.1 Microbecide Corporation Information
6.22.2 Microbecide Antibacterial (Drug) Resistance Description, Business Overview
6.22.3 Microbecide Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.22.4 Microbecide Products Offered
6.22.5 Microbecide Recent Development
6.23 Morphochem
6.23.1 Morphochem Corporation Information
6.23.2 Morphochem Antibacterial (Drug) Resistance Description, Business Overview
6.23.3 Morphochem Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.23.4 Morphochem Products Offered
6.23.5 Morphochem Recent Development
6.24 Nabriva Therapeutics
6.24.1 Nabriva Therapeutics Corporation Information
6.24.2 Nabriva Therapeutics Antibacterial (Drug) Resistance Description, Business Overview
6.24.3 Nabriva Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.24.4 Nabriva Therapeutics Products Offered
6.24.5 Nabriva Therapeutics Recent Development
6.25 NanoSafe Coatings
6.25.1 NanoSafe Coatings Corporation Information
6.25.2 NanoSafe Coatings Antibacterial (Drug) Resistance Description, Business Overview
6.25.3 NanoSafe Coatings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.25.4 NanoSafe Coatings Products Offered
6.25.5 NanoSafe Coatings Recent Development
6.26 Novexel
6.26.1 Novexel Corporation Information
6.26.2 Novexel Antibacterial (Drug) Resistance Description, Business Overview
6.26.3 Novexel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.26.4 Novexel Products Offered
6.26.5 Novexel Recent Development
6.27 Osel
6.27.1 Osel Corporation Information
6.27.2 Osel Antibacterial (Drug) Resistance Description, Business Overview
6.27.3 Osel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.27.4 Osel Products Offered
6.27.5 Osel Recent Development
6.28 VenatoRx Pharmaceuticals
6.28.1 VenatoRx Pharmaceuticals Corporation Information
6.28.2 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Description, Business Overview
6.28.3 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.28.4 VenatoRx Pharmaceuticals Products Offered
6.28.5 VenatoRx Pharmaceuticals Recent Development
6.29 AAIPharma Services
6.29.1 AAIPharma Services Corporation Information
6.29.2 AAIPharma Services Antibacterial (Drug) Resistance Description, Business Overview
6.29.3 AAIPharma Services Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.29.4 AAIPharma Services Products Offered
6.29.5 AAIPharma Services Recent Development
6.30 ANTABIO
6.30.1 ANTABIO Corporation Information
6.30.2 ANTABIO Antibacterial (Drug) Resistance Description, Business Overview
6.30.3 ANTABIO Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2015-2020)
6.30.4 ANTABIO Products Offered
6.30.5 ANTABIO Recent Development

7 Antibacterial (Drug) Resistance Manufacturing Cost Analysis
7.1 Antibacterial (Drug) Resistance Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price Trend
7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Antibacterial (Drug) Resistance
7.4 Antibacterial (Drug) Resistance Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Antibacterial (Drug) Resistance Distributors List
8.3 Antibacterial (Drug) Resistance Customers

9 Market Dynamics
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis

10 Global Market Forecast
10.1 Global Antibacterial (Drug) Resistance Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Antibacterial (Drug) Resistance by Type (2021-2026)
10.1.2 Global Forecasted Revenue of Antibacterial (Drug) Resistance by Type (2021-2026)
10.2 Antibacterial (Drug) Resistance Market Estimates and Projections by Indication
10.2.1 Global Forecasted Sales of Antibacterial (Drug) Resistance by Indication (2021-2026)
10.2.2 Global Forecasted Revenue of Antibacterial (Drug) Resistance by Indication (2021-2026)
10.3 Antibacterial (Drug) Resistance Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Antibacterial (Drug) Resistance by Region (2021-2026)
10.3.2 Global Forecasted Revenue of Antibacterial (Drug) Resistance by Region (2021-2026)
11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Tables

Table 1. Global Antibacterial (Drug) Resistance Sales (K Units) Growth Rate Comparison by Type (2015-2026)
Table 2. Global Antibacterial (Drug) Resistance Sales (K Units) Comparison by Indication: 2020 VS 2026
Table 3. Global Antibacterial (Drug) Resistance Market Size by Type (K Units) (US$ Million) (2020 VS 2026)
Table 4. Global Key Antibacterial (Drug) Resistance Manufacturers Covered in This Study
Table 5. Global Antibacterial (Drug) Resistance Sales (K Units) by Manufacturers (2015-2020)
Table 6. Global Antibacterial (Drug) Resistance Sales Share by Manufacturers (2015-2020)
Table 7. Global Antibacterial (Drug) Resistance Revenue (Million USD) by Manufacturers (2015-2020)
Table 8. Global Antibacterial (Drug) Resistance Revenue Share by Manufacturers (2015-2020)
Table 9. Global Market Antibacterial (Drug) Resistance Average Price (USD/Unit) of Key Manufacturers (2015-2020)
Table 10. Manufacturers Antibacterial (Drug) Resistance Sales Sites and Area Served
Table 11. Manufacturers Antibacterial (Drug) Resistance Product Types
Table 12. Global Antibacterial (Drug) Resistance Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Antibacterial (Drug) Resistance by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antibacterial (Drug) Resistance as of 2019)
Table 14.Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Main Points Interviewed from Key Antibacterial (Drug) Resistance Players
Table 16. Global Antibacterial (Drug) Resistance Sales (K Units) by Region (2015-2020)
Table 17. Global Antibacterial (Drug) Resistance Sales Market Share by Region (2015-2020)
Table 18. Global Antibacterial (Drug) Resistance Revenue (Million US$) by Region (2015-2020)
Table 19. Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2015-2020)
Table 20. North America Antibacterial (Drug) Resistance Sales by Country (2015-2020) (K Units)
Table 21. North America Antibacterial (Drug) Resistance Sales Market Share by Country (2015-2020)
Table 22. North America Antibacterial (Drug) Resistance Revenue by Country (2015-2020) (US$ Million)
Table 23. North America Antibacterial (Drug) Resistance Revenue Market Share by Country (2015-2020)
Table 24. Europe Antibacterial (Drug) Resistance Sales by Country (2015-2020) (K Units)
Table 25. Europe Antibacterial (Drug) Resistance Sales Market Share by Country (2015-2020)
Table 26. Europe Antibacterial (Drug) Resistance Revenue by Country (2015-2020) (US$ Million)
Table 27. Europe Antibacterial (Drug) Resistance Revenue Market Share by Country (2015-2020)
Table 28. Asia Pacific Antibacterial (Drug) Resistance Sales by Region (2015-2020) (K Units)
Table 29. Asia Pacific Antibacterial (Drug) Resistance Sales Market Share by Region (2015-2020)
Table 30. Asia Pacific Antibacterial (Drug) Resistance Revenue by Region (2015-2020) (US$ Million)
Table 31. Asia Pacific Antibacterial (Drug) Resistance Revenue Market Share by Region (2015-2020)
Table 32. Latin America Antibacterial (Drug) Resistance Sales by Country (2015-2020) (K Units)
Table 33. Latin America Antibacterial (Drug) Resistance Sales Market Share by Country (2015-2020)
Table 34. Latin America Antibacterial (Drug) Resistance Revenue by Country (2015-2020) (US$ Million)
Table 35. Latin America Antibacterial (Drug) Resistance Revenue Market Share by Country (2015-2020)
Table 36. Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2015-2020) (K Units)
Table 37. Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share by Country (2015-2020)
Table 38. Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country (2015-2020) (US$ Million)
Table 39. Middle East and Africa Antibacterial (Drug) Resistance Revenue Market Share by Country (2015-2020)
Table 40. Global Antibacterial (Drug) Resistance Sales (K Units) by Type (2015-2020)
Table 41. Global Antibacterial (Drug) Resistance Sales Share by Type (2015-2020)
Table 42. Global Antibacterial (Drug) Resistance Revenue (Million US$) by Type (2015-2020)
Table 43. Global Antibacterial (Drug) Resistance Revenue Share by Type (2015-2020)
Table 44. Global Antibacterial (Drug) Resistance Price (USD/Unit) by Type (2015-2020)
Table 45. Global Antibacterial (Drug) Resistance Sales (K Units) by Indication (2015-2020)
Table 46. Global Antibacterial (Drug) Resistance Sales Market Share by Indication (2015-2020)
Table 47. Global Antibacterial (Drug) Resistance Sales Growth Rate by Indication (2015-2020)
Table 48. Melinta Therapeutics Corporation Information
Table 49. Melinta Therapeutics Description and Business Overview
Table 50. Melinta Therapeutics Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 51. Melinta Therapeutics Main Product
Table 52. Melinta Therapeutics Recent Development
Table 53. Allergan Corporation Information
Table 54. Allergan Description and Business Overview
Table 55. Allergan Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 56. Allergan Main Product
Table 57. Allergan Recent Development
Table 58. Merck Corporation Information
Table 59. Merck Description and Business Overview
Table 60. Merck Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 61. Merck Main Product
Table 62. Merck Recent Development
Table 63. Abbott Laboratories Corporation Information
Table 64. Abbott Laboratories Description and Business Overview
Table 65. Abbott Laboratories Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 66. Abbott Laboratories Main Product
Table 67. Abbott Laboratories Recent Development
Table 68. Pfizer Corporation Information
Table 69. Pfizer Description and Business Overview
Table 70. Pfizer Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 71. Pfizer Main Product
Table 72. Pfizer Recent Development
Table 73. GSK Corporation Information
Table 74. GSK Description and Business Overview
Table 75. GSK Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 76. GSK Main Product
Table 77. GSK Recent Development
Table 78. PENDOPHARM Corporation Information
Table 79. PENDOPHARM Description and Business Overview
Table 80. PENDOPHARM Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 81. PENDOPHARM Main Product
Table 82. PENDOPHARM Recent Development
Table 83. Absynth Biologics Corporation Information
Table 84. Absynth Biologics Description and Business Overview
Table 85. Absynth Biologics Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 86. Absynth Biologics Main Product
Table 87. Absynth Biologics Recent Development
Table 88. Achaogen Corporation Information
Table 89. Achaogen Description and Business Overview
Table 90. Achaogen Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 91. Achaogen Main Product
Table 92. Achaogen Recent Development
Table 93. Acino Holdings Corporation Information
Table 94. Acino Holdings Description and Business Overview
Table 95. Acino Holdings Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 96. Acino Holdings Main Product
Table 97. Acino Holdings Recent Development
Table 98. Aventis Pharma Corporation Information
Table 99. Aventis Pharma Description and Business Overview
Table 100. Aventis Pharma Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 101. Aventis Pharma Main Product
Table 102. Aventis Pharma Recent Development
Table 103. Austell Laboratories Corporation Information
Table 104. Austell Laboratories Description and Business Overview
Table 105. Austell Laboratories Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 106. Austell Laboratories Main Product
Table 107. Austell Laboratories Recent Development
Table 108. Assembly Biosciences Corporation Information
Table 109. Assembly Biosciences Description and Business Overview
Table 110. Assembly Biosciences Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 111. Assembly Biosciences Main Product
Table 112. Assembly Biosciences Recent Development
Table 113. Arpida Corporation Information
Table 114. Arpida Description and Business Overview
Table 115. Arpida Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 116. Arpida Main Product
Table 117. Arpida Recent Development
Table 118. Demuris Corporation Information
Table 119. Demuris Description and Business Overview
Table 120. Demuris Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 121. Demuris Main Product
Table 122. Demuris Recent Development
Table 123. Evolva Holding Corporation Information
Table 124. Evolva Holding Description and Business Overview
Table 125. Evolva Holding Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 126. Evolva Holding Main Product
Table 127. Evolva Holding Recent Development
Table 128. ContraFect Corporation Information
Table 129. ContraFect Description and Business Overview
Table 130. ContraFect Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 131. ContraFect Main Product
Table 132. ContraFect Recent Development
Table 133. Cerexa Corporation Information
Table 134. Cerexa Description and Business Overview
Table 135. Cerexa Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 136. Cerexa Main Product
Table 137. Cerexa Recent Development
Table 138. InterMune Corporation Information
Table 139. InterMune Description and Business Overview
Table 140. InterMune Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 141. InterMune Main Product
Table 142. InterMune Recent Development
Table 143. Isis Pharmaceuticals Corporation Information
Table 144. Isis Pharmaceuticals Description and Business Overview
Table 145. Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 146. Isis Pharmaceuticals Main Product
Table 147. Isis Pharmaceuticals Recent Development
Table 148. Lyndra Corporation Information
Table 149. Lyndra Description and Business Overview
Table 150. Lyndra Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 151. Lyndra Main Product
Table 152. Lyndra Recent Development
Table 153. Microbecide Corporation Information
Table 154. Microbecide Description and Business Overview
Table 155. Microbecide Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 156. Microbecide Main Product
Table 157. Microbecide Recent Development
Table 158. Morphochem Corporation Information
Table 159. Morphochem Description and Business Overview
Table 160. Morphochem Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 161. Morphochem Main Product
Table 162. Morphochem Recent Development
Table 163. Nabriva Therapeutics Corporation Information
Table 164. Nabriva Therapeutics Description and Business Overview
Table 165. Nabriva Therapeutics Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 166. Nabriva Therapeutics Main Product
Table 167. Nabriva Therapeutics Recent Development
Table 168. NanoSafe Coatings Corporation Information
Table 169. NanoSafe Coatings Description and Business Overview
Table 170. NanoSafe Coatings Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 171. NanoSafe Coatings Main Product
Table 172. NanoSafe Coatings Recent Development
Table 173. Novexel Corporation Information
Table 174. Novexel Description and Business Overview
Table 175. Novexel Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 176. Novexel Main Product
Table 177. Novexel Recent Development
Table 178. Osel Corporation Information
Table 179. Osel Description and Business Overview
Table 180. Osel Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 181. Osel Main Product
Table 182. Osel Recent Development
Table 183. VenatoRx Pharmaceuticals Corporation Information
Table 184. VenatoRx Pharmaceuticals Description and Business Overview
Table 185. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 186. VenatoRx Pharmaceuticals Main Product
Table 187. VenatoRx Pharmaceuticals Recent Development
Table 188. AAIPharma Services Corporation Information
Table 189. AAIPharma Services Description and Business Overview
Table 190. AAIPharma Services Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 191. AAIPharma Services Main Product
Table 192. AAIPharma Services Recent Development
Table 193. ANTABIO Corporation Information
Table 194. ANTABIO Description and Business Overview
Table 195. ANTABIO Antibacterial (Drug) Resistance Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 196. ANTABIO Main Product
Table 197. ANTABIO Recent Development
Table 198. Production Base and Market Concentration Rate of Raw Material
Table 199. Key Suppliers of Raw Materials
Table 200. Antibacterial (Drug) Resistance Distributors List
Table 201. Antibacterial (Drug) Resistance Customers List
Table 202. Antibacterial (Drug) Resistance Market Trends
Table 203. Antibacterial (Drug) Resistance Opportunities and Drivers
Table 204. Antibacterial (Drug) Resistance Market Challenges
Table 205. Global Antibacterial (Drug) Resistance Sales (K Units) Forecast by Type (2021-2026)
Table 206. Global Antibacterial (Drug) Resistance Sales Market Share Forecast by Type (2021-2026)
Table 207. Global Antibacterial (Drug) Resistance Revenue (Million US$) Forecast by Type (2021-2026)
Table 208. Global Antibacterial (Drug) Resistance Revenue (Million US$) Market Share Forecast by Type (2021-2026)
Table 209. Global Antibacterial (Drug) Resistance Sales (K Units) Forecast by Indication (2021-2026)
Table 210. Global Antibacterial (Drug) Resistance Revenue (Million US$) Forecast by Indication (2021-2026)
Table 211. Global Antibacterial (Drug) Resistance Sales (K Units) Forecast by Region (2021-2026)
Table 212. Global Antibacterial (Drug) Resistance Sales Market Share Forecast by Region (2021-2026)
Table 213. Global Antibacterial (Drug) Resistance Revenue Forecast by Region (2021-2026) (US$ Million)
Table 214. Global Antibacterial (Drug) Resistance Revenue Market Share Forecast by Region (2021-2026)
Table 215. Research Programs/Design for This Report
Table 216. Key Data Information from Secondary Sources
Table 217. Key Data Information from Primary Sources

List of Figures

Figure 1. Picture of Antibacterial (Drug) Resistance
Figure 2. Global Antibacterial (Drug) Resistance Sales Market Share by Type: 2020 VS 2026
Figure 3. Telavancin (Vibativ) Product Picture
Figure 4. Ceftaroline Fosamil (Teflaro/ Zinforo) Product Picture
Figure 5. Fidaxomicin (Dificid / Dificlir) Product Picture
Figure 6. Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Product Picture
Figure 7. Dalbavancin (Dalvance/ Xydalba) Product Picture
Figure 8. Tedizolid Phosphate (Siv